Sumitomo Chemical Company (4005) Q3 2025 earnings summary

Executive summary

• Core operating income for Q3 FY2024 reached ¥60.1 billion, reversing a prior year loss of ¥113.9 billion, driven by strong performance in Pharma and ICT & Mobility segments.

• Net income attributable to owners was ¥28.6 billion, a year-on-year improvement of ¥138.4 billion, despite a temporary loss related to Petro Rabigh.

• Sales revenue for Q3 FY2024 rose 5.4% year-over-year to ¥1,904.8 billion, with all profit categories improving.

• The company is on track for a V-shaped recovery in FY2024, with profit increasing quarter after quarter.

• Segment reorganization was implemented in October 2024, affecting reporting structure.

Financial highlights

• Core operating income improved by ¥173.9 billion year-over-year; operating income reached ¥145.4 billion, up ¥306.1 billion.

• Free cash flow for Q3 FY2024 was ¥197.5 billion, up ¥410.2 billion year-over-year.

• Return on equity improved to 3.0% from -9.4% year-over-year.

• Overseas sales revenue ratio increased to 69.8%.

• Basic earnings per share improved to ¥17.47 from a loss of ¥67.13 in Q3 FY2023.

Outlook and guidance

• FY2024 full-year forecast remains unchanged: sales revenue ¥2,600.0 billion, core operating income ¥100.0 billion, operating income ¥180.0 billion, net income ¥25.0 billion.

• Dividend forecast maintained at ¥9.00 per share for the year.

• Segment forecasts revised: downward for Essentials & Green Materials and Agro & Life Solutions, upward for Pharma.

• Business environment remains uncertain with weak global growth and continued geopolitical risks.

• No change to previously announced guidance as of this quarter.